Rathkopf DP, Choudhury MR, Rasco AD, Lakhani D, Hawley N, Srinivas JE, et al
The approval of this first in a new class of cell therapies for solid tumors defines a regulatory path for TIL, which will unlock more innovation in the industry and ultimately benefit patients with cancer, Jason Bock, CEO of CTMC, a joint venture between biotech Resilience and MD Anderson Cancer Center, told BioSpace in an email
Additional GLP-1 drugs include Trulicity (dulaglutide), Victoza (liraglutide), Saxenda (liraglutide), Byetta (exenatide), Zepbound (tirzepatide), and Mounjaro (tirzepatide), and they all have risks and benefits
Clinicians considering GLP-1 receptor agonists for post-bariatric weight regain typically conduct a comprehensive assessment to identify contributing factors
2015;309(3):E21423
[PubMed: 11408427] 69